Pharmacological Trials

ADVANCE

International Phase 3 study funded by the pharmaceutical company Baxalta, to evaluate the efficacy, safety and tolerability of a subcutaneous immunoglobulin infusion for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

– study concluded

EMBARK (Aducanumab)

“A Phase 3b, open-label, multicenter safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302, and 221AD205.”

This pharmacological experimentation is financed by the company "Biogen", which uses the CRO IQVIA RDS Italy srl

– study concluded

PROMISE (Protein Misfolding)

Multicenter (IRCCS Besta), randomized, phase II, futility-design pharmacological study for amyotrophic lateral sclerosis and guanabenz.

– study concluded

ENGAGED

An international, multicenter Phase 3 study funded by the pharmaceutical company BIOGEN to evaluate the efficacy and safety of an innovative drug, called aducanumab, intended for the treatment of patients with early-onset Alzheimer's disease.

– study concluded

CREATE

International, multicenter, randomized, double-blind, Phase 3 study funded by the pharmaceutical company ROCHE, to evaluate the efficacy and safety of crenezumab in patients with mild Alzheimer's disease (probable AD/prodromal AD).

– study concluded

MS-COG

A multicenter study funded by the pharmaceutical company BIOGEN on healthy subjects, aimed at establishing reference values ​​for the MS-COG cognitive assessment scale in a population comparable to that of patients affected by Multiple Sclerosis.

– study concluded

GRADUATE

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety study evaluating the efficacy and safety of gantenerumab in patients with early (prodromal to mild) Alzheimer's disease.

– study concluded